JP2003325192A - 乳癌予後ポートフォリオ - Google Patents
乳癌予後ポートフォリオInfo
- Publication number
- JP2003325192A JP2003325192A JP2003097226A JP2003097226A JP2003325192A JP 2003325192 A JP2003325192 A JP 2003325192A JP 2003097226 A JP2003097226 A JP 2003097226A JP 2003097226 A JP2003097226 A JP 2003097226A JP 2003325192 A JP2003325192 A JP 2003325192A
- Authority
- JP
- Japan
- Prior art keywords
- portfolio
- genes
- dna
- human
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004393 prognosis Methods 0.000 title claims abstract description 19
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 16
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 108
- 230000014509 gene expression Effects 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 56
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 6
- 238000002493 microarray Methods 0.000 claims description 22
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000010208 microarray analysis Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 101
- 239000000523 sample Substances 0.000 description 20
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 239000003550 marker Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000010837 poor prognosis Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150106899 28 gene Proteins 0.000 description 1
- 101150094765 70 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36878902P | 2002-03-29 | 2002-03-29 | |
| US60/368789 | 2002-03-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003325192A true JP2003325192A (ja) | 2003-11-18 |
| JP2003325192A5 JP2003325192A5 (enExample) | 2006-03-09 |
Family
ID=29215884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003097226A Pending JP2003325192A (ja) | 2002-03-29 | 2003-03-31 | 乳癌予後ポートフォリオ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7473526B2 (enExample) |
| EP (1) | EP1367138B1 (enExample) |
| JP (1) | JP2003325192A (enExample) |
| KR (1) | KR20030078805A (enExample) |
| CN (1) | CN1495274A (enExample) |
| AR (1) | AR039213A1 (enExample) |
| AU (1) | AU2003203557B2 (enExample) |
| BR (1) | BR0303092A (enExample) |
| CA (1) | CA2422303A1 (enExample) |
| DE (1) | DE60317606T2 (enExample) |
| MX (1) | MXPA03002864A (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007088971A1 (ja) * | 2006-02-03 | 2007-08-09 | Messengerscape Co., Ltd. | がん予後判定に利用できる遺伝子群 |
| JP2007528218A (ja) * | 2004-02-20 | 2007-10-11 | ベリデックス・エルエルシー | 乳癌の予後診断 |
| JP2011526487A (ja) * | 2008-07-02 | 2011-10-13 | セントロ・デ・インベステイガイシオネス・エネルゲテイカス，メデイオアムビエンタレス・イ・テクノロヒカス・（セ．イ．エ．エメ．ア．テ．） | 乳癌のゲノムフィンガープリント |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| US20050003422A1 (en) * | 2003-07-01 | 2005-01-06 | Mitch Reponi | Methods for assessing and treating cancer |
| JP2007532142A (ja) * | 2004-04-23 | 2007-11-15 | エグザジェン ダイアグノスティクス インコーポレイテッド | 乳がん遺伝子発現バイオマーカー |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| BRPI0720219A2 (pt) | 2006-12-08 | 2013-12-24 | Univ Iowa State Res Found Inc | Genes de planta envolvidos em absorção e metabolismo de nitrato |
| CN105224827B (zh) * | 2008-07-01 | 2019-12-24 | 小利兰·斯坦福大学托管委员会 | 用于发展ivf治疗协议的分析数据的计算机系统和存储介质 |
| GB0821787D0 (en) * | 2008-12-01 | 2009-01-07 | Univ Ulster | A genomic-based method of stratifying breast cancer patients |
| US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
| US10011876B2 (en) | 2010-11-23 | 2018-07-03 | Krisani Biosciences Pvt. Ltd | Method and system for prognosis and treatment of diseases using portfolio of genes |
| KR101287600B1 (ko) * | 2011-01-04 | 2013-07-18 | 주식회사 젠큐릭스 | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US635152A (en) * | 1899-06-05 | 1899-10-17 | Melancthon S Shotwell | Car-body bolster. |
| US6350576B1 (en) | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| AU5310296A (en) | 1995-03-17 | 1996-10-08 | John Wayne Cancer Institute | Detection of melanoma or breast metastases with a multiple marker assay |
| US6275814B1 (en) | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| US6037129A (en) | 1998-05-28 | 2000-03-14 | Medical University Of South Carolina | Multi-marker RT-PCR panel for detecting metastatic breast cancer |
| US6175624B1 (en) * | 1999-03-05 | 2001-01-16 | Centurion International, Inc. | Method for connecting a battery circuit in a cellular telephone |
| MXPA01009369A (es) | 1999-03-15 | 2003-06-06 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal. |
| JP2004507202A (ja) * | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」 |
| US6175824B1 (en) | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| RU2251838C2 (ru) | 1999-07-15 | 2005-05-20 | Рисерч Дивелопмент Фаундейшн | Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование |
| WO2003070889A2 (en) * | 2002-02-19 | 2003-08-28 | Idec Pharmaceuticals Corporation | Prostate specific genes and the use thereof in design or therapeutics |
| US20050054826A1 (en) * | 2003-05-19 | 2005-03-10 | Rosetta Inpharmatics Llc | Human diaphanous-3 gene and methods of use therefor |
-
2003
- 2003-03-21 US US10/393,590 patent/US7473526B2/en not_active Expired - Fee Related
- 2003-03-28 CA CA002422303A patent/CA2422303A1/en not_active Abandoned
- 2003-03-28 BR BR0303092-0A patent/BR0303092A/pt not_active IP Right Cessation
- 2003-03-28 AU AU2003203557A patent/AU2003203557B2/en not_active Expired - Fee Related
- 2003-03-29 KR KR10-2003-0019842A patent/KR20030078805A/ko not_active Withdrawn
- 2003-03-29 CN CNA031312063A patent/CN1495274A/zh active Pending
- 2003-03-31 DE DE60317606T patent/DE60317606T2/de not_active Expired - Fee Related
- 2003-03-31 MX MXPA03002864A patent/MXPA03002864A/es not_active Application Discontinuation
- 2003-03-31 JP JP2003097226A patent/JP2003325192A/ja active Pending
- 2003-03-31 EP EP03252026A patent/EP1367138B1/en not_active Revoked
- 2003-04-01 AR ARP030101134A patent/AR039213A1/es not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528218A (ja) * | 2004-02-20 | 2007-10-11 | ベリデックス・エルエルシー | 乳癌の予後診断 |
| WO2007088971A1 (ja) * | 2006-02-03 | 2007-08-09 | Messengerscape Co., Ltd. | がん予後判定に利用できる遺伝子群 |
| JP2011526487A (ja) * | 2008-07-02 | 2011-10-13 | セントロ・デ・インベステイガイシオネス・エネルゲテイカス，メデイオアムビエンタレス・イ・テクノロヒカス・（セ．イ．エ．エメ．ア．テ．） | 乳癌のゲノムフィンガープリント |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2422303A1 (en) | 2003-09-29 |
| AU2003203557B2 (en) | 2007-05-24 |
| DE60317606D1 (de) | 2008-01-03 |
| BR0303092A (pt) | 2004-09-08 |
| KR20030078805A (ko) | 2003-10-08 |
| EP1367138A2 (en) | 2003-12-03 |
| US20030190656A1 (en) | 2003-10-09 |
| US7473526B2 (en) | 2009-01-06 |
| AU2003203557A1 (en) | 2003-10-23 |
| DE60317606T2 (de) | 2008-10-23 |
| AR039213A1 (es) | 2005-02-09 |
| EP1367138A3 (en) | 2004-03-10 |
| CN1495274A (zh) | 2004-05-12 |
| MXPA03002864A (es) | 2004-08-11 |
| EP1367138B1 (en) | 2007-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577813C (zh) | 肿瘤诊断组合物 | |
| US20030194734A1 (en) | Selection of markers | |
| AU2003203557B2 (en) | Breast cancer prognostic portfolio | |
| US9587279B2 (en) | Thyroid tumors identified | |
| US20040146907A1 (en) | Methods and compositions for detecting dysplasia | |
| CA2430981A1 (en) | Gene expression profiling of primary breast carcinomas using arrays of candidate genes | |
| BRPI0708534A2 (pt) | ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b | |
| US20040241725A1 (en) | Lung cancer detection | |
| BRPI0616090A2 (pt) | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida | |
| CA2403946A1 (en) | Genes expressed in foam cell differentiation | |
| AU2008203227A1 (en) | Colorectal cancer prognostics | |
| US20030013099A1 (en) | Genes regulated by DNA methylation in colon tumors | |
| CA3067730A1 (en) | Methods for detection of plasma cell dyscrasia | |
| KR20070090110A (ko) | 위 암종으로부터의 림프절 전이의 검출법 | |
| AU2004205270B2 (en) | Colorectal cancer prognostics | |
| HK1141054A (en) | Tumor diagnostic composition | |
| CA3064732A1 (en) | Methods for melanoma detection | |
| CN1890385A (zh) | 结肠直肠癌相关基因 | |
| CN101405406A (zh) | 诊断胰癌的方法 | |
| WO2013059152A2 (en) | Methods and kits for selection of a treatment for breast cancer | |
| MXPA04008401A (en) | Colorectal cancer prognostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060123 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060123 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090310 |